133 related articles for article (PubMed ID: 31671400)
1. Metabolite analysis-aided diagnosis of papillary thyroid cancer.
Chen J; Hu Q; Hou H; Wang S; Zhang Y; Luo Y; Chen H; Deng H; Zhu H; Zhang L; Liu H; Wang A; Liu Y
Endocr Relat Cancer; 2019 Dec; 26(12):829-841. PubMed ID: 31671400
[TBL] [Abstract][Full Text] [Related]
2. Serum-plasma matched metabolomics for comprehensive characterization of benign thyroid nodule and papillary thyroid carcinoma.
Huang FQ; Li J; Jiang L; Wang FX; Alolga RN; Wang MJ; Min WJ; Ma G; Zhao YJ; Wang SL; Yu Y; Chen X; Zhu D; Zhu J; Wang G; Xia T; Sang JF; Lai MD; Li P; Zhu W; Qi LW
Int J Cancer; 2019 Feb; 144(4):868-876. PubMed ID: 30318614
[TBL] [Abstract][Full Text] [Related]
3. Metabolomics of papillary thyroid carcinoma tissues: potential biomarkers for diagnosis and promising targets for therapy.
Shang X; Zhong X; Tian X
Tumour Biol; 2016 Aug; 37(8):11163-75. PubMed ID: 26935059
[TBL] [Abstract][Full Text] [Related]
4. Integrative metabolomic characterization identifies plasma metabolomic signature in the diagnosis of papillary thyroid cancer.
Yu S; Liu C; Hou Y; Li J; Guo Z; Chen X; Zhang L; Peng S; Hong S; Xu L; Li X; Liu R; Chen S; Li B; Weng Z; Li Y; Lv W; Yu J; Xiao H
Oncogene; 2022 Apr; 41(17):2422-2430. PubMed ID: 35279704
[TBL] [Abstract][Full Text] [Related]
5. Plasma metabolites analysis of patients with papillary thyroid cancer: A preliminary untargeted
Razavi SA; Mahmanzar M; Nobakht M Gh BF; Zamani Z; Nasiri S; Hedayati M
J Pharm Biomed Anal; 2024 Apr; 241():115946. PubMed ID: 38241910
[TBL] [Abstract][Full Text] [Related]
6. Combined metabolomic and lipidomic analysis uncovers metabolic profile and biomarkers for papillary thyroid carcinoma.
Wang Z; Yang Y; Xing Y; Si D; Wang S; Lin J; Li C; Zhang J; Yin D
Sci Rep; 2023 Oct; 13(1):17666. PubMed ID: 37848492
[TBL] [Abstract][Full Text] [Related]
7. Serum MMP-2 as a potential predictive marker for papillary thyroid carcinoma.
Shi Y; Su C; Hu H; Yan H; Li W; Chen G; Xu D; Du X; Zhang P
PLoS One; 2018; 13(6):e0198896. PubMed ID: 29949618
[TBL] [Abstract][Full Text] [Related]
8. Altered expression of DLG1-AS1 distinguished papillary thyroid carcinoma from benign thyroid nodules.
He T; Wang H; Sun J; Wu J; Gong F; Li S; Wang H; Li Y
BMC Endocr Disord; 2019 Nov; 19(1):122. PubMed ID: 31718630
[TBL] [Abstract][Full Text] [Related]
9. Predictive significance of serum dipeptidyl peptidase-IV in papillary thyroid carcinoma.
Zhang N; Cong X; Zhou D; Guo L; Yuan C; Xu D; Su C
Cancer Biomark; 2019; 24(1):7-17. PubMed ID: 30594915
[TBL] [Abstract][Full Text] [Related]
10. Cell-free DNA methylation biomarker for the diagnosis of papillary thyroid carcinoma.
Hong S; Lin B; Xu M; Zhang Q; Huo Z; Su M; Ma C; Liang J; Yu S; He Q; Su Z; Li Y; Liu R; Guo Z; Lv W; Xiao H
EBioMedicine; 2023 Apr; 90():104497. PubMed ID: 36868052
[TBL] [Abstract][Full Text] [Related]
11. Identification of β-hydroxybutyrate as a potential biomarker for female papillary thyroid cancer.
Chen J; Hou H; Chen H; Luo Y; He Y; Zhang L; Zhang Y; Liu H; Zhang F; Liu Y; Wang A; Hu Q
Bioanalysis; 2019 Mar; 11(6):461-470. PubMed ID: 30892060
[No Abstract] [Full Text] [Related]
12. Diagnostic significance of elevated expression of HBME-1 in papillary thyroid carcinoma.
Chen YJ; Zhao RM; Zhao Q; Li BY; Ma QY; Li X; Chen X
Tumour Biol; 2016 Jul; 37(7):8715-20. PubMed ID: 26738867
[TBL] [Abstract][Full Text] [Related]
13. Serum microRNAs as biomarkers for the diagnosis of papillary thyroid carcinoma: a meta-analysis.
Chen Y; Dong B; Huang L; Huang H
Bosn J Basic Med Sci; 2022 Oct; 22(6):862-871. PubMed ID: 35678022
[TBL] [Abstract][Full Text] [Related]
14. Altered Serum MicroRNA Profile May Serve as an Auxiliary Tool for Discriminating Aggressive Thyroid Carcinoma from Nonaggressive Thyroid Cancer and Benign Thyroid Nodules.
Zhang A; Wang C; Lu H; Chen X; Ba Y; Zhang C; Zhang CY
Dis Markers; 2019; 2019():3717683. PubMed ID: 31636734
[TBL] [Abstract][Full Text] [Related]
15. Machine learning reveals salivary glycopatterns as potential biomarkers for the diagnosis and prognosis of papillary thyroid cancer.
Ren X; Shu J; Wang J; Guo Y; Zhang Y; Yue L; Yu H; Chen W; Zhang C; Ma J; Li Z
Int J Biol Macromol; 2022 Aug; 215():280-289. PubMed ID: 35660041
[TBL] [Abstract][Full Text] [Related]
16. Exosomal miRNAs are potential diagnostic biomarkers between malignant and benign thyroid nodules based on next-generation sequencing.
Pan Q; Zhao J; Li M; Liu X; Xu Y; Li W; Wu S; Su Z
Carcinogenesis; 2020 Mar; 41(1):18-24. PubMed ID: 31560760
[TBL] [Abstract][Full Text] [Related]
17. Non-invasive diagnosis of papillary thyroid microcarcinoma: a NMR-based metabolomics approach.
Lu J; Hu S; Miccoli P; Zeng Q; Liu S; Ran L; Hu C
Oncotarget; 2016 Dec; 7(49):81768-81777. PubMed ID: 27835583
[TBL] [Abstract][Full Text] [Related]
18. Significance of BRAF V600E Mutation and Cytomorphological Features for the Optimization of Papillary Thyroid Cancer Diagnostics in Cytologically Indeterminate Thyroid Nodules.
Beiša A; Kvietkauskas M; Beiša V; Stoškus M; Ostanevičiūtė E; Jasiūnas E; Griškevičius L; Šeinin D; Šileikytė A; Strupas K
Exp Clin Endocrinol Diabetes; 2019 Apr; 127(4):247-254. PubMed ID: 29566402
[TBL] [Abstract][Full Text] [Related]
19. Metabolic Profiles and Blood Biomarkers to Discriminate between Benign Thyroid Nodules and Papillary Carcinoma, Based on UHPLC-QTOF-ESI
Berinde GM; Socaciu AI; Socaciu MA; Petre GE; Socaciu C; Piciu D
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542465
[TBL] [Abstract][Full Text] [Related]
20. Complement C4-A and Plasminogen as Potential Biomarkers for Prediction of Papillary Thyroid Carcinoma.
Wang Y; Zhou S; Wang D; Wei T; Zhu J; Li Z
Front Endocrinol (Lausanne); 2021; 12():737638. PubMed ID: 34803909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
